Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases, Parkinson's disease, Thalassemia, Primary Immunodeficiency Disease) - Global Forecast to 2023

[104 Pages Report] The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from USD 5.44 billion in 2017, at a CAGR of 11.1% during the forecast period. The base year considered for the report is 2017 and the forecast period is 2018–2023.

Objectives of the Study

• To define, measure, and describe the global market by type, therapy, and region. To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
• To forecast the size of the market segments in North America, Europe, Asia Pacific, and the RoW
• To strategically analyze the market structure and profile the key players in the global market and comprehensively analyze their core competencies
• To track and analyze company developments such as partnerships, agreements, and collaborations; expansions; product approvals; and product launches in the market

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global wearable injectors market and estimate the size of other dependent submarkets. Various secondary sources such as International Association of Cancer Registries (IACR), International Society of Geriatric Oncology (SIOG), International Society of Paediatric Oncology (SIOP), International Agency for Research on Cancer (IARC), International Diabetes Federation (IDF), International Council of Cardiovascular Prevention and Rehabilitation (ICCPR), American Association for Cancer Research (AACR), American Society of Hematology, American Diabetes Association, American Association of Diabetes Educators (AADE), American Heart Association, European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), European Cancer Organization (ECCO), European Association for the Study of Diabetes (EASD), European Society of Endocrinology, European Society of Cardiology, European Parkinson's Disease Association (EPDA), Asian Clinical Oncology Society (ACOS), Asian Cancer Foundation, Asian Association for the Study of Diabetes (AASD), ASEAN Federation of Endocrine Societies, Asian Pacific Society of Cardiology, Cancer Foundation of China (CFC), Japan Endocrine Society, Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Diabetes Association (ADJ), Latin American Diabetes Association (ALAD), press releases, and annual reports of the companies have been used to identify and collect information useful for the study of this market.

Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess the dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:

To know about the assumptions considered for the study, download the pdf brochure

The major players in the global wearable injectors market are Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutic Corporation (US), Valeritas (US), and SteadyMed Therapeutics (US). The other prominent players in this market are Ypsomed (Switzerland), Becton Dickinson and Company (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).

Target Audience:

• Wearable injectors manufacturing companies
• Original equipment manufacturing companies
• Suppliers and distributors of wearable injectors
• Healthcare service providers
• Teaching hospitals and academic medical centers
• Health insurance players
• Government bodies/municipal corporations
• Regulatory bodies
• Medical research institutes
• Business research and consulting service providers
• Venture capitalists
• Market research and consulting firms

Scope of the Report:

The research report categorizes the market into the following segments and subsegments:

Wearable Injectors Market, by Type

• On-body injectors
• Off-body injectors

Wearable Injectors Market, by Therapy

• Immuno-oncology
• Diabetes
• Cardiovascular Diseases
• Other Therapies (Parkinson’s disease, Thalassemia, and Primary Immunodeficiency Disorders)

Wearable Injectors Market, by Region

• North America
• Europe
• Asia Pacific
• Rest of the World

Available customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Product Analysis

• Product matrix, which gives a detailed comparison of the product portfolios of each company

Company Information

• Detailed analysis and profiling of additional market players (up to 3)

Table of Contents

1 Introduction (Page No. - 11)
    1.1 Objectives of Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 15)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
           2.2.2 Primary Research
                    2.2.2.1 Key Data From Primary Sources
                    2.2.2.2 Key Industry Insights
    2.3 Market Size Estimation Methodology
    2.4 Market Data Validation and Triangulation
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 25)

4 Premium Insights (Page No. - 28)
    4.1 Wearable Injectors Market: Overview
    4.2 Global Market, By Type, 2018 vs 2023
    4.3 Geographic Analysis: Global Market, By Therapy
    4.4 Geographic Snapshot: Global Market

5 Wearable Injectors Market Overview (Page No. - 32)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growing Prevalence of Chronic Diseases
                    5.2.1.2 Favorable Reimbursement Scenario in Major Markets
                    5.2.1.3 Technological Advancements and Design Development
           5.2.2 Restraints
                    5.2.2.1 Preference for Alternative Drug Delivery Modes
           5.2.3 Opportunities
                    5.2.3.1 Increasing Demand for Biologics and MABS
           5.2.4 Challenges
                    5.2.4.1 Unfavorable Reimbursement Structure in Developing Countries

6 By Type (Page No. - 35)
    6.1 Introduction
    6.2 On-Body Injectors
    6.3 Off-Body Injectors

7 By Therapy (Page No. - 39)
    7.1 Introduction
    7.2 Immuno-Oncology
    7.3 Diabetes
    7.4 Cardiovascular Diseases
    7.5 Other Therapies

8 By Region (Page No. - 46)
    8.1 Introduction
    8.2 North America
           8.2.1 US
           8.2.2 Canada
    8.3 Europe
           8.3.1 Germany
           8.3.2 UK
           8.3.3 France
           8.3.4 Rest of Europe
    8.4 Asia Pacific
           8.4.1 Japan
           8.4.2 China
           8.4.3 India
           8.4.4 RoAPAC
    8.5 Rest of the World

9 Competitive Landscape (Page No. - 74)
    9.1 Overview
    9.2 Market Share Analysis
    9.3 Market Share Analysis, By Therapy
           9.3.1 Immuno-Oncology
           9.3.2 Amgen
           9.3.3 Diabetes
           9.3.4 Medtronic
           9.3.5 Insulet Corporation
           9.3.6 Cardiovascular Diseases
           9.3.7 United Therapeutics
    9.4 Competitive Scenario
           9.4.1 Product Launches and Approvals
           9.4.2 Expansions
           9.4.3 Agreements, Collaborations, and Partnerships

10 Company Profiles (Page No. - 79)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     10.1 Amgen
     10.2 Medtronic PLC
     10.3 Insulet Corporation
     10.4 Ypsomed
     10.5 Becton, Dickinson and Company
     10.6 Tandem Diabetes Care, Inc.
     10.7 United Therapeutics Corporation
     10.8 Valeritas, Inc.
     10.9 Enable Injections
     10.10 Steadymed Therapeutics
     10.11 Sensile Medical (A Part of Gerresheimer)

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

11 Appendix (Page No. - 98)
     11.1 Discussion Guide
     11.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     11.3 Available Customizations
     11.4 Related Reports
     11.5 Author Details

List of Tables (46 Tables)

Table 1 Wearable Injectors (WI) Market, By Type, 2016–2023 (USD Billion)
Table 2 On-Body WI Market, By Country, 2016–2023 (USD Million)
Table 3 Off-Body WI Market, By Country, 2016–2023 (USD Million)
Table 4 Global Market, By Therapy, 2016–2023 (USD Billion)
Table 5 Global Market for Immuno-Oncology, By Country, 2016–2023 (USD Million)
Table 6 Insulin Devices Available for Diabetic Patients
Table 7 Global Market for Diabetes, By Country, 2016–2023 (USD Million)
Table 8 Global Market for Cardiovascular Diseases, By Country, 2016–2023 (USD Million)
Table 9 Global Market for Other Therapies, By Country, 2016–2023 (USD Million)
Table 10 Global Market, By Region, 2016-2023 (USD Million)
Table 11 North America: Wearable Injectors Market, By Country, 2016-2023 (USD Million)
Table 12 North America: Market, By Therapy, 2016-2023 (USD Million)
Table 13 North America: Market, By Type, 2016-2023 (USD Million)
Table 14 US: Market, By Therapy, 2016-2023 (USD Million)
Table 15 US: Market, By Type, 2016-2023 (USD Million)
Table 16 Canada: Market, By Therapy, 2016-2023 (USD Million)
Table 17 Canada: Market, By Type, 2016-2023 (USD Million)
Table 18 Recent Developments in the Wearable Injectors Market in Europe, 2015–2018
Table 19 Europe: Market, By Country, 2016-2023 (USD Million)
Table 20 Europe: Market, By Therapy, 2016-2023 (USD Million)
Table 21 Europe: Market, By Type, 2016-2023 (USD Million)
Table 22 Germany: Market, By Therapy, 2016-2023 (USD Million)
Table 23 Germany: Market, By Type, 2016-2023 (USD Million)
Table 24 UK: Market, By Therapy, 2016-2023 (USD Million)
Table 25 UK: Market, By Type, 2016-2023 (USD Million)
Table 26 France: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 27 France: Market, By Type, 2016-2023 (USD Million)
Table 28 RoE: Market, By Therapy, 2016-2023 (USD Million)
Table 29 RoE: Market, By Type, 2016-2023 (USD Million)
Table 30 Asia Pacific: Market, By Country, 2016-2023 (USD Million)
Table 31 Asia Pacific: Market, By Therapy, 2016-2023 (USD Million)
Table 32 Asia Pacific: Market, By Type, 2016-2023 (USD Million)
Table 33 Japan: Wearable Injectors Market, By Therapy, 2016-2023 (USD Million)
Table 34 Japan: Market, By Type, 2016-2023 (USD Million)
Table 35 China: Market, By Therapy, 2016-2023 (USD Million)
Table 36 China: Market, By Type, 2016-2023 (USD Million)
Table 37 India: Market, By Therapy, 2016-2023 (USD Million)
Table 38 India: Market, By Type, 2016-2023 (USD Million)
Table 39 RoAPAC: Market, By Therapy, 2016-2023 (USD Million)
Table 40 RoAPAC: Wearable Injectors Market, By Type, 2016-2023 (USD Million)
Table 41 Conferences in Africa, Brazil, and the Middle East (2016–2018)
Table 42 RoW: Market, By Therapy, 2016-2023 (USD Million)
Table 43 RoW: Market, By Type, 2016-2023 (USD Million)
Table 44 Product Launches and Approvals
Table 45 Expansions
Table 46 Agreements, Collaborations, and Partnerships

List of Figures (30 Figures)

Figure 1 Wearable Injectors Market: Research Methodology Steps
Figure 2 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Research Design
Figure 6 Data Triangulation Methodology
Figure 7 Immuno-Oncology Therapy Segment to Dominate the Wearable Injectors Market in 2018
Figure 8 On-Body Injectors to Account for the Largest Share of the Global Market in 2018
Figure 9 North America to Witness the Highest Market Growth During the Forecast Period
Figure 10 Growing Prevalence of Chronic Diseases is Driving Market Growth
Figure 11 On-Body Injectors Segment to Dominate the Market in 2018
Figure 12 Immuno-Oncology Segment to Command the Largest Share of the Market in 2018
Figure 13 North America to Witness the Highest Growth Rate During the Forecast Period
Figure 14 Wearable Injectors Market: Drivers, Restraints, Opportunities, & Challenges
Figure 15 Global Market, By Type, 2018 vs 2023 (USD Billion)
Figure 16 Wearable Injectors Market, By Therapy, 2018 vs 2023 (USD Billion)
Figure 17 North America to Command the Largest Market Share in 2018
Figure 18 North America: Market Snapshot
Figure 19 Europe: Market Snapshot
Figure 20 Asia Pacific: Market Snapshot
Figure 21 RoW: Market Snapshot
Figure 22 Strategies Adopted By Market Players (2014–2018)
Figure 23 Amgen: Company Snapshot (2017)
Figure 24 Medtronic PLC: Company Snapshot (2017)
Figure 25 Insulet Corporation: Company Snapshot (2017)
Figure 26 Ypsomed: Company Snapshot (2017)
Figure 27 BD: Company Snapshot (2017)
Figure 28 Tandem Diabetes Care: Company Snapshot (2017)
Figure 29 United Therapeutics Corporation: Company Snapshot (2017)
Figure 30 Valeritas: Company Snapshot (2017)

The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period. The growth of this market is primarily driven by the growing prevalence of chronic diseases (such as cancer, diabetes, and CVD); favorable reimbursement scenario in major markets; and technological advancements in injector devices. However, the preference for alternative drug delivery modes and a poor reimbursement structure in developing countries is expected to limit the adoption of wearable injector devices to a certain extent.

The market is segmented on the basis of type, therapy, and region. Based on type, the market is segmented into on-body and off-body injectors. The on-body wearable injectors segment is expected to account for the larger market share in 2018, while the off-body injectors segment is projected to witness the highest growth rate during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.

Based on therapy, the global wearable injectors market is segmented into immune-oncology, diabetes, cardiovascular diseases, and other therapies (such as Parkinson’s disease, thalassemia, and primary immunodeficiency disease). The immuno-oncology segment is expected to account for the largest share of the market in 2018. The large share of this segment can be attributed to the high prevalence of cancer across the globe.

By region, the global market is segmented into North America, Europe, Asia Pacific, and the RoW. The North American region is expected to account for the largest market share in 2018. The large share of this region can be attributed to the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases and favorable reimbursement scenario in this region.

The global wearable injectors market is dominated by Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutic Corporation (US), and Valeritas (US). These players adopted growth strategies such as product launches, product approvals, agreements, and expansions to maintain and enhance their positions in the market. Other prominent players in the market include Ypsomed (Switzerland), Becton, Dickinson and Company (US), SteadyMed Therapeutics (US), Enable Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst